Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519691-10-00

Acronym

ANDROMEDA-SHOCK-2

Enrollment

500

Registered

2025-01-23

Start date

2022-05-27

Completion date

2025-07-28

Last updated

2025-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Brief summary

The primary outcome is a hierarchical composite of all cause mortality within 28 days, time to cessation of vital support (truncated at 28 days) and length of hospital stay (truncated at 28 days).

Detailed description

All-cause mortality within 28 days (Time Frame: 28days)

Interventions

DRUGSuero Fisiológico Vitulia 0

DRUG9 % solución para perfusión

DRUGLactato Ringer Braun

DRUGsolução para perfusão

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary outcome is a hierarchical composite of all cause mortality within 28 days, time to cessation of vital support (truncated at 28 days) and length of hospital stay (truncated at 28 days).	—

Secondary

Measure	Time frame
All-cause mortality within 28 days (Time Frame: 28days)	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026